Paper Details

  1. Home
  2. Paper Details

Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction.

Author: ArunBanu, AshfaqRaheela, BuDawei, DooleyWilliam, EuhusDavid, FlockhartDavid, GrantMichael, HuntKelly, LewisCheryl, MillerAlexander, O'ShaughnessyJoyce, SarodeVenetia, XiaWeiya, XieXian-Jin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Tamoxifen reduced breast epithelial cell proliferation by downregulating ETV4 and ETV5, two Ets oncogene transcription factor family members. This effect was independent of CYP2D6 genotypes or effects on estradiol, ESR1, or IGFs.
Paper Details　
Original Abstract of the Article :
Five years of tamoxifen reduces breast cancer risk by nearly 50% but is associated with significant side effects and toxicities. A better understanding of the direct and indirect effects of tamoxifen in benign breast tissue could elucidate new mechanisms of breast carcinogenesis, suggest novel chemo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/21778330

データ提供：米国国立医学図書館（NLM）

Tamoxifen: A New Perspective on Breast Cancer Prevention

The fight against breast cancer, like an endless desert battle, continues to evolve. This research explores the potential mechanisms underlying tamoxifen's breast cancer preventive effects, focusing on its impact on ets oncogene family members ETV4 and ETV5.

Tamoxifen: A Potential for Targeted Action

The authors investigated the effects of tamoxifen on benign breast tissue in women at increased risk for breast cancer. They found that tamoxifen downregulated the expression of ETV4 and ETV5, potentially contributing to its breast cancer preventive effects. It's like discovering a hidden water source in the desert, offering a potential new weapon in the fight against this disease. This research suggests that tamoxifen may act by targeting specific genes involved in breast cancer development.

A Promising Avenue for Breast Cancer Prevention

This study provides valuable insights into the potential mechanisms underlying tamoxifen's breast cancer preventive effects. It opens up new avenues for research and development of targeted therapies to combat this disease. This research reminds us that the fight against cancer is a continuous journey, requiring ongoing research and innovative approaches to find new and effective ways to prevent and treat this deadly disease.

Dr. Camel's Conclusion

This research offers a promising new perspective on tamoxifen's breast cancer preventive effects. The study highlights the potential role of ETV4 and ETV5 in breast cancer development and suggests that tamoxifen may act by targeting these genes. This research underscores the importance of ongoing research to unravel the complex mechanisms underlying cancer and to develop targeted therapies that can effectively prevent and treat this disease.
Date :
  1. Date Completed 2012-03-12
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

21778330

DOI: Digital Object Identifier

NIHMS313563

Related Literature

Article Analysis
・Effects of tamoxifen
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.